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Since the original description of the therapeutic action of Co~ynebacterium parvum in 
a syngeneic murine tumor system over a decade ago (1), many reports have appeared 
(2-4) describing the anti-tumor action of this agent against syngeneic and autochtho- 
nous  tumors  in  animals,  and  against  tumors  in  man.  The  efficacy of anti-tumor 
therapy with C. parvum varies greatly among different tumor-host systems and depends 
on such factors as tumor immunogenicity (3, 5), tumor size and location (2, 3, 6), the 
amount of C. parvum used (7, 8), and its route of administration (2). Depending upon 
the route of administration, C. parvum may elicit different anti-tumor mechanisms (2). 
Intravenous  administration  appears to  favor the  generation  of nonspecific effector 
mechanisms, which are expressed by activated macrophages or natural killer cells (2, 
3, 9-11). Intralesional therapy with C. paroum, on the other hand, is thought to favor 
the generation of T  cell-mediated anti-tumor immunity, as evidenced by the finding 
that the anti-tumor action depends on the presence of a  functional T  cell system (8, 
12,  13).  Moreover, it has been shown that animals that have regressed their tumors 
after intralesional therapy with C. parvum display specific resistance to the growth of 
a  tumor challenge implant  (7,  14),  and possess T  cells that are capable of passively 
transferring anti-tumor resistance to normal recipients (12,  14). On the other hand, C. 
parvum has also been shown to enhance the growth of tumors, presumably because of 
its capacity to induce the generation of suppressor mechanisms (15,  16). 
The  main  purpose of this  paper is  to  describe  a  model currently  being used  to 
analyze the potential and limitations of tumor immunotherapy with C. parvum. It will 
show  that  when  P815  tumor  cells  are  admixed  with  C.  parvum  and  implanted 
subcutaneously, the tumor that emerges grows for 9 d and then regresses. It will also 
show  that  the  mechanism  responsible  for this  regression  is  capable of causing  the 
regression  of  an  untreated  test  tumor  growing  at  a  distant  site,  and  that  this 
therapeutic action is based on a T  cell-mediated immune response to tumor-specific 
transplantation antigens. It will show, finally, that the immunotherapeutic action of 
the C. parvum-tumor cell admixture against  a  distant  test tumor is limited to a  test 
tumor below  a  certain  critical  size.  The companion  paper  (17)  will  deal  with  the 
reasons for this therapeutic limitation. 
* Supported by grant CA-16642 from  the National Cancer Institute, grant IM-266 from The American 
Cancer Society, and grant RR-05705 from the Division of Research Resources, National Institutes of 
Health. 
:~ Supported by a fellowship from  the J. M. Foundation. 
J. Exp. MED. © The Rockefeller  University Press • 0022-1007/81/09/609/12 St.00  609 
Volume 154  September  1981  609-620 610  ANTI-TUMOR  ACTION OF CORYNEBACTERIUM PARVUM 
Materials and Methods 
Mice.  B6D2  (C57BL/6  x  DBA/2)F1,  CB6  (BALB/c  ×  C57BL/6)F1,  DBA/2,  and 
BALB/c mice of either sex were used when they were 8-12 wk of age. They were produced in 
the Animal Breeding Facility of the Trudeau Institute. 
Tumors.  The P815 mastocytoma syngeneic in DBA/2 mice was originally obtained from 
Dr. Virginia Evans of the National Cancer Institute, Tissue Culture Section, Bethesda, Md. A 
methylcholanthrene-induced tumor (Meth A fibrosarcoma)  l syngeneic in BALB/c mice was 
obtained from Dr. Lloyd J. Old of the Memorial Sloan-Kettering  Cancer Center, New York. 
The CaD2 mammary carcinoma syngeneic in DBA/2 mice was obtained from The Jackson 
Laboratory, Bar Harbor, Maine, and the BP3 fibrosarcoma was induced in C57BL/6 mice by 
subcutaneous injection ofbenzpyrene. The CaD2 and BP3 tumors were shown previously to be 
nonimmunogenic  (18). 
The P815 mastocytoma and the Meth A fibrosarcoma were subcultured for several weeks in 
Fisher's medium (Grand Island Biological Co.,  Grand Island, N.  Y.)  containing 15%  heat- 
inactivated fetal calf serum (FCS) before being passaged several times as ascites in the peritoneal 
cavities of syngeneic mice. Ascites  Meth A and P815 tumor cells, and BP3 and CaD2 cells 
grown in vitro were harvested and resuspended in Fisher's medium containing 20% FCS and 
10% dimethyl sulfoxide, dispensed into a large number of small vials, and cryopreserved over 
liquid nitrogen. Before  each  experiment, a  vial was  thawed  and  the cells  were  washed  in 
Dulbecco's phosphate-buffered saline (PBS). For experiments, the P815 mastocytoma and the 
Meth  A  fibrosarcoma were  grown as ascites  for  6  d  in B6D2  mice, and harvested in PBS 
containing 10 U  heparin/ml. After two washes  in PBS,  they were resuspended to the desired 
concentration in PBS for injection. The CaD2 and BP3 tumors were grown in vitro in RPMI 
1640 containing 15% heat-inactivated horse serum. Confluent monolayers were harvested from 
disposable plastic tissue culture flasks (3024; Falcon Labware, Div. of Becton Dickinson & Co., 
Oxnard, Calif.)  in trypsin-EDTA (Grand Island Biological  Co.).  The trypsinized cells were 
washed twice in PBS containing 1% FCS and resuspended to the desired concentration in PBS 
for implantation. Tumors were initiated in the hind footpads of mice by implanting  the desired 
number of cells in a volume of 0.05 ml PBS with a 30.5-gauge needle. The growth of footpad 
tumors was monitored by measuring increases against time in the dorsoventral thickness of the 
foot with dial calipers. 
Irradiation of Cells.  P815 ascites tumor cells were harvested in PBS containing 10 U heparin/ 
ml, and after several washes in PBS they were resuspended in RPMI 1640 containing 5% FCS 
at  10  r cells/ml. The cells were  then exposed to 4,500  rad of gamma rays from a cesium-137 
irradiator at a midphantom dose rate of 29.5 rad/min. They were then washed twice in PBS 
and resuspended in PBS for implantation. Pilot experiments showed that  10  7 irradiated tumor 
cells implanted in a hind footpad failed to form a tumor during a 60-d period of observation. 
T Cell-deficient Mice.  4-wk-old mice were rendered T cell defcient by thymectomy, followed 
7 d later by lethal (900 rad) whole-body gamma irradiation. They were infused intravenously 
immediately after irradiation with  10  7 syngeneic bone marrow cells and used in experiments 6 
wk later. 
C. paroum.  Formalin-killed C. paroum was supplied as a suspension (7 mg/ml) in physiologic 
saline by Dr.  R.  L.  Tuttle of the  Burroughs Wellcome Company, Research Triangle Park, 
N. C. Lot  771/A was used in all experiments. An admixture containing a known number of 
replicating, or gamma-irradiated, nonreplicating  tumor cells with a known weight of C. parvum 
was injected subcutaneously into the hind footpads of mice. 
Passive  Transfer of Anti-Tumor Resistance.  Cells were obtained from the spleens and draining 
lymph nodes of tumor-immune donors (see Results). To harvest the cells, spleens and lymph 
nodes were diced into small pieces and gently pushed through a 200-mesh stainless steel screen 
into cold PBS that contained 1% heat-inactivated FCS. The suspension was triturated with a 
Pasteur pipette to break up clumps, and passed through several layers of sterile surgical gauze. 
Cells  were  washed  and  resuspended to  the  desired  concentration in  PBS  for  intravenous 
infusion. Sera from the same tumor-immune donors were  recovered from clotted blood and 
l Abbreviations used in this paper: FCS, fetal calf serum; Meth A, methylcholanthrene A; PBS, phosphate- 
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stored at -70°C in 1.0-ml aliquots. The aliquots were thawed and injected intravenously as 
needed. 
Recipient mice were infused intravenously  with 1.5 ×  108 spleen cells, or 5 X 107 lymph node 
cells from tumor-immune donors 1 h before receiving a challenge implant of 106 P815 tumor 
cells in a hind footpad. The protective ability of serum from tumor-immune donors was tested 
by giving recipients 0.5 ml intravenously 1 h before the challenge implant, and 1 and 2 d later. 
In some experiments, mice that received serum were pretreated 7 d earlier with an intradermal 
injection of 100 Izg C. parvum. The growth of the challenge implant was monitored by measuring 
increases against time in the dorsoventral thickness of the foot with dial calipers. 
Treatment with Anti-Thy-l.2 Antibody.  Lyophilized anti-Thy-l.2 monoelonal IgM antibody 
(Sera Lab, Accurate Chemical and Scientific Corporation, Hicksville, N. Y.) was dissolved in 
a volume of distilled water equal to the original volume of ascites. The antibody solution was 
aliquoted and stored  at  -70°C until needed.  When tested  against mouse thymocytes, the 
antibody had a cytotoxic titer of > 1:50,000. Lymph node cells were treated at 5 X 107/ml with 
a  1:1,000  dilution of the  antibody for  45  rain at  10°C.  The cells  were  then washed  and 
incubated for 30 rain at 37°C in the same volume of a  1:15 dilution of rabbit serum (Low-Tox- 
M rabbit complement; Accurate Chemical and Scientific Corporation) as a source of comple- 
ment. After washing twice in PBS containing 5% FCS, the cells were resuspended to the desired 
concentration in PBS for intravenous infusion. 
Results 
Tumor Growth and Regression  in the Presence of C. parvum.  Earlier studies conducted in 
this laboratory (19) revealed that the implantation  of 108 Meth A tumor cells admixed 
with 20 Izg C. parvum resulted in 7-9 d of tumor growth, followed by tumor regression 
over the next 2-3 wk. Confirmation of this finding with the P815 is shown in Fig.  1, 
which compares the growth of 2 X  106 P815 tumor cells with 2 ×  10  ~ Meth A  tumor 
cells when both types of tumor cells were implanted as admixtures with  100 #g  C. 
parvum.  It  can be seen with  both  tumors that  tumor growth  in the  presence of C. 
parvum was similar to the growth of control tumors over the first 9 d. After this time, 
however,  the  tumors containing C.  parvum  regressed,  whereas  control tumors  grew 
progressively to kill their hosts. The percentage of regressed tumors that regrew after 
30 d  varied from 0 to 40% between experiments. 
Therapeutic Effect of C. parvum-Tumor  Cell Admixture  on a  Distant  Tumor.  As the first 
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F[o.  1.  Evidence  that when 2 x  l0  s P815 mastocytoma cells are admixed with lO0 #g C. parvum 
(left panel) or 2 X l0  s Meth A fibrosarcoma cells are admixed with 100 Ixg C. parvum (right panel) 
and injected into a hind footpad, the tumor that  emerges grows progressively for 9 d and then 
completely regresses. Means of five mice per time-point. 612  ANTI-TUMOR ACTION OF CORYNEBACTERIUM PARVUM 
step  in  investigating the  mechanisms  of C.  parvum-induced  regression,  experiments 
were  designed  to determine whether  the regression of the  tumor  that  contained  C. 
parvum  was  a  local  phenomenon,  or  whether  it  was  associated  instead  with  the 
generation  of  an  anti-tumor  mechanism  capable  of causing  the  regression  of  an 
untreated test tumor growing simultaneously at a distant site. This involved injecting 
mice in the right hind footpad with an admixture of 2  ×  106 tumor cells and  100 #g 
C. parvum,  and in the left hind footpad with 2  ×  106 tumor cells alone. It can be seen 
in Fig. 2 that the treated and untreated tumors behaved similarly. In both cases, a  9- 
d period of tumor growth was followed by progressive and complete tumor regression. 
Fig. 2  shows,  in addition, that  tumor cells needed to be admixed with  C. parvum  to 
cause the regression of a  distant test tumor, because the injection of 100 I~g C. parvum 
alone  in  the  right  hind  footpad  had  no  effect  on  the  growth  of a  tumor  in  the 
contralateral side. As was the case with the tumors that arose from tumor-C, parvum 
admixtures, a  variable proportion (0-30%)  of the test tumors that regressed began to 
regrow after 28 d. 
Requirement for  Tumor  Immunogenicity  to  Induce Systemic  Anti-Tumor  Resistance.  The 
preceding results show that tumor cells and C. parvum must be injected as an admixture 
to cause a  distant tumor to regress. The experiments in this section were designed to 
determine whether this therapeutic action of C. parvum  depends on the tumor being 
immunogenic. To investigate this, the nonimmunogenic BP3  fibrosarcoma was used. 
Mice were injected in the right hind footpad with  100/.tg of C. parvum  admixed with 
2  ×  10  n BP3  cells and  in  the  left hind  footpad with  2  ×  10  n BP3  cells alone.  The 
results in Fig. 3 show that although the rate of growth of this tumor in the presence 
of C. parvum was slower after day 9, growth of the untreated tumor in the contralateral 
footpad was  unaffected.  Based on  this result, and a  similar result  (data not  shown) 
with  the  nonimmunogenic  CaD2  mammary  carcinoma,  it  is  apparent  that  the 
therapeutic action of an  admixture  of tumor  cells and  C. parvum  against a  distant 
tumor  is  limited  to  immunogenic  tumors.  It  is  apparent  that  the  reduced  rate  of 
growth of the tumor containing C. parvum was caused by nonspecific mechanisms (19) 
that developed locally in response to C. parvum. 
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Fie. 2.  Evidence that growth and regression ofa C. parvum-treated tumor in the right hind footpad 
are concordant  with growth and regression of an untreated tumor in the contralateral footpad. 
Mice were implanted with 2 ×  l0  s tumor cells admixed with  100 I~g C. parvurn in the right hind 
footpad and with 2 ×  l0  s tumor cells alone in the left hind footpad. Tumor growth and regression 
in these mice was compared with the growth of 2 ×  L0  n tumor cells in control mice. The right panel 
shows that implanting 100 g.g C. paroum alone in the right hind footpad had no effect on the growth 
of 2 ×  106 P815 cells implanted at the same time in the left hind footpad. Means of five mice per 
time-point. E.  S.  DYE,  R. J.  NORTH,  AND C.  D.  MILLS  613 
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FIG.  3.  Evidence that the therapeutic action of C. ~arvurn depends on the tumor being immuno- 
genic. The right panel shows that implanting 2 ×  I0  BP3 fibrosarcoma cells admixed with  100 #g 
C. parvum in the right hind footpad had no effect on growth of 2 ×  l0  s BP3 cells implanted alone in 
the left hind footpad. The left panel shows the behavior of 2 X  l0  s BP3 cells implanted either alone 
or admixed with 100 #g C. parvum. Means of five mice per time-point. 
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FIG. 4.  Evidence that implanting gamma-irradiated, nonreplicating tumor cells admixed with C 
parvum can induce regression of a distant test tumor. The effect of injecting decreasing numbers of 
irradiated tumor cells admixed with 100 #g C. parvum in the right hind footpad  on the growth of a 
contralateral test tumor implanted at the same time in the left hind footpad is shown. Admixtures 
containing  either 107 irradiated P815 cells or 2 ×  106 replicating P815 cells caused regression of the 
test  tumor. Progressively decreasing  the number of nonreplicating tumor cells in the admixture 
resulted  in progressive  reductions in its therapeutic effect  against the contralateral test  tumor. 
Means of five mice per time-point. Irradiated P815 cells: A,  10 X 106; -~, 5 X  10s; [-'1, 2.5 ×  106; 
A, 1.2 ×  10  e. O, 2 ×  10  ° viable P815 cells. 
Substitution of Gamma-irradiated Tumor Cells for Replicating  Tumor Cells in the Therapeutic 
Admixture.  Studies  by  others  (8,  14)  have  shown  that  local  implantation  of either 
replicating tumor  cells  or  nonreplicating tumor  cells  admixed  with  C. parvum  can 
render mice immune  to the growth  of a  tumor implant. The results shown in Fig. 4 
are in keeping with these findings. They show that  107 irradiated, nonreplicating P815 
tumor cells admixed with C parvum were as effective as 2 ×  106 replicating tumor cells 
in  the  admixture  in  causing  the  regression  of a  P815  test  tumor  growing  in  the 
contralateral  footpad.  Fig.  4  shows,  in  addition,  that  decreasing  the  number  of 
irradiated  tumor  cells  in  the  admixture  resulted  in  a  decreasing  therapeutic  effect 
against  the  contralateral  test  tumor.  This  result  indicates  that  the  strength  of the 614  ANTI-TUMOR  ACTION OF  CORYNEBACTERIUM PARVUM 
therapeutic response engendered by the admixture was determined by the quantity 
of tumor antigens. 
Immunotherapeutic Action of C. parvum-Tumor Cell Admixture Is T  Cell Dependent.  The 
foregoing results indicate that the therapeutic action of an admixture of tumor ceils 
and C. parvum against a  distant test tumor is based on an immune response to tumor 
antigens.  The experiments in  this  section  were designed  to determine whether  this 
immune response is T  cell dependent. The first experiment was designed to investigate 
whether  the  C. parvum-tumor  cell admixture  engendered  a  therapeutic  response in 
mice made T  cell  deficient  by thymectomy and  irradiation,  or in  mice  that  were 
immunosuppressed by whole-body gamma irradiation.  It can be seen in Fig. 5  that 
neither T  cell-deficient mice, nor gamma-irradiated mice were capable of causing the 
regression  of the  tumor that  emerged  from the  therapeutic  admixture,  or  the  test 
tumor growing in the contralateral side.  These results clearly demonstrate the need 
for an intact T  cell system for C. parvum-induced  regression. 
The second experiment was designed to determine whether the onset of C. parvum- 
induced  tumor regression was concordant with the acquisition of T  cells capable of 
adoptively immunizing normal recipients against the growth of a tumor cell implant. 
Mice were  implanted  in  one  hind  footpad with  an  admixture  containing  2  ×  10  6 
P815 cells and  100 ~g C. parvum, and in the contralateral footpad with 2 ×  106 P815 
cells alone. These mice served as donors of serum, spleen cells, and lymph node cells 
for passive transfer into recipients that received a tumor challenge implant in the left 
hind footpad. The results of an experiment that used cells harvested from donors at 
the onset  of C. parvum-induced  tumor regression  on  day 9, are presented  in  Fig.  6, 
where it can be seen that passive transfer of 1.5  ×  10  a spleen cells, or 5 ×  107 lymph 
node cells adoptively immunized normal recipients against  growth of the challenge 
implant. In contrast, recipients infused intravenously with 0.5 ml of"immune" serum 
at the time of giving the challenge implant, and 24 and 48 h  later, failed to express 
anti-tumor immunity.  Mice pretreated with  100 #g C. parvum 7 d  before treatment 
with immune serum also failed to suppress the growth of the challenge implant. 
That the adoptive anti-tumor resistance was mediated by T  cells is shown in Fig. 
60. 
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FIG. 5.  Evidence  that  an  intact  T  cell  system is  necessary for a  C.  parvum-tumor admixture to 
engender  a  therapeutic  response.  Mice  made  T  cell  deficient  (TXB)  by  whole-body  gamma 
irradiation  and  thymectomy  and  protected  with  bone  marrow, or  mice  subjected  to  900  rad 
irradiation  1 h  before the experiment, were unable to regress the tumor that  emerged from the 
admixture in the right hind footpad, or from 1)815 cells alone in the left hind footpad. Means of five 
mice per time-point. E.  S.  DYE,  R+ j.  NORTH,  AND  C.  D.  MILLS  615 
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Fie.  6.  Evidence that lymph node cells (LN) and spleen cells (SPC), but not serum, from donors 
that were in the process ofsimuhaneously  regressing  a C. paroum-containing tumor and a contralateral 
test tumor were capable of adoptively immunizing normal recipients against the growth of a  tumor 
implant. Recipients received either 1.5 ×  10  a spleen cells, or 5 ×  10  7 lymph node cells intravenously 
I h before challenge with P815 ceils in the left hind footpad. Recipients of serum received three 0.5- 
ml infusions of serum on d  0,  1, and 2 of tumor growth. Serum failed to transfer any anti-tumor 
immunity even when it was infused into mice pretreated 7 d  earlier with a  subcutaneous injection 
of tO0 leg C. patroon (right panel). Means of five mice per time-point. 
o 
50-  ~/tJ 
i  .L  TUMOR  ,~u-  CONTROL // 
•  -  V  ~  ANTI-THY-L.2 
av-  J  .'+"--IMMUNE  CELLS 
20"  S  ''n" 
NJ 
I0-  ~ff  IMMUNE  CELLS  . 
....  I  '  I  '  E'+'  t'+'¢O'  +'4'h 
DAYS 
FzG.  7.  Evidence that T  cells are responsible for the therapeutic action of the  C. parvum-tumor 
admixture against a  distant test tumor. Lymph node cells (10  a)  harvested from donors regressing 
their tumors failed to passively transfer immunity to growth of a  tumor implant if the cells were 
treated with anti-Thy-l.2 and complement. Means of five mice per time-point. 
7, where it can be seen that treatment of lymph node cells from 9-d donors with Thy- 
1.2 serum and complement completely abolished their protective capacity. 
Specificity of C.  paroum-potentiated Anti-Tumor Immunity.  The  foregoing  results  are 
consistent with the interpretation that C. parvum-induced anti-tumor resistance results 
in the generation of a population oft  cells sensitized to tumor-specific transplantation 
antigens.  The purpose of the experiments in this section was to determine whether 
these  T  cells  are  specific  for  the  tumor  that  elicits  their  production.  This  was 
investigated by determining whether the response generated against the P815  mas- 
tocytoma admixed with  C. paroum would  cause the  regression  of an  unrelated  test 
tumor growing at a  distant site on the same host. Mice injected intradermally in the 
belly region with 2 ×  106 P815 cells admixed with 100 Ixg C. paroum were injected with 
106 P815 cells in the left hind footpad, and with 2.5  ×  105 CaD2 tumor cells in the 
right hind  footpad. Control tumor growth was measured in mice injected in a  hind 
footpad with either test tumor alone.  It can be seen in  Fig.  8  that  the therapeutic 
action of the C. paroum-augmented  anti-tumor response was specific for the P815 test 616  ANTI-TUMOR  ACTION  OF  CORYNEBACTERIUM PARVUM 
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Fro.  8.  Evidence showing that the anti-tumor response elicited by the admixture of C. parvum and 
P815 cells is specific for the P815  tumor.  Mice injected intradermally with 2  ×  106 P815  cells 
admixed with 100 #g C. paroum were implanted in the right hind footpad with 2.5 x  105 CaD2 cells, 
and in the left hind footpad with l0  s P815 cells. The response to the admixture caused the P815 test 
tumor to regress after 9 d of growth, but had no effect on growth of the CaD2 test tumor. Means of 
five mice per time-point. 
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Fro.  9.  Effect on growth of a test tumor in the left hind footpad when the therapeutic admixture 
containing 2 ×  l0  s P815 cells plus 100 #g C. parvum was injected in the right hind footpad 6, 4, or 
2 d before, or at the time of, or 2, 4, or 6 d after implanting the test tumor. The later the therapeutic 
admixture was given with respect to implanting the test tumor (106 P815 cells), the larger the test 
tumor grew before regression  commenced and the less complete was regression.  Except for the case 
of giving the admixture on day 6 of test tumor growth, the onset of regression always occurred 
between 8 and 10 d after injecting the admixture. Means of five mice per time-point. 
tumor,  in that the admixture  of C. parvum and  P815 cells had  no therapeutic  effect at 
all against the CaD2  tumor. 
Limitation of Therapeutic Action of C. parvum- Tumor Cell Admixture.  It has been reported 
on numerous  occasions (2-4) that the intralesional injection of immunoadjuvants  fails 
to  cause  the  regression  of  tumors  that  have  grown  beyond  a  certain  size.  It  was 
anticipated,  therefore,  that  the immunotherapeutic  effect  of injecting an  admixture 
of C. parvum and tumor  cells would be similarly restricted to distant test tumors  below 
a  certain  size.  This  was  investigated  by  an  experiment  in  which  the  therapeutic 
admixture  was  injected  in  the  right  hind  footpad  at  different  times  before  or  after 
implanting  the  test  tumor  in  the  contralateral  footpad.  The  results  in  Fig.  9  show 
that,  whereas  injecting the  admixture  before  or  at  the  time  of implanting  the  test 
tumor  resulted in complete  regression of the test tumor,  injecting the admixture  after E.  S.  DYE,  R.  J.  NORTH,  AND  C.  D.  MILLS  617 
implanting the test tumor resulted in partial or no regression. It can be seen that the 
onset of regression of the test tumor always occurred between 8 and 10 d after injecting 
the admixture.  This meant  that  the earlier the admixture was given, the less  time 
there was for the test tumor to grow, and the smaller it was at  the time regression 
commenced. Practically no therapeutic effect was obtained when the admixture was 
given on the 6th d  of growth of the test tumor. These results show, therefore,  that 
immunotherapy with an admixture of C. parvum and tumor cells is limited to relatively 
small tumors. 
Discussion 
This paper shows that implanting P815 tumor cells, or Meth A  fibrosarcoma cells 
admixed with C. parvum results in the emergence of a tumor that grows for a period of 
9-10  d  and  then  regresses.  It shows,  in  addition,  that  regression of the  C. parvum- 
treated tumor failed to occur in  mice that were gamma-irradiated, or made T  cell 
deficient by thymectomy and lethal irradiation, and restored with bone marrow ceils. 
This evidence, together with the finding that  the onset of C. parvum-induced  tumor 
regression was associated with the generation in the spleen and draining node of T 
cells that were capable of adoptively immunizing normal mice against growth of a 
tumor  implant,  is consistent  with  the  hypothesis  that  the  therapeutic  effect  of C. 
parvum is based on its capacity to potentiate the generation of T  cell-mediated anti- 
tumor immunity. The results are therefore in agreement with previous results from 
this  (12,  14)  and other laboratories  (7, 8), showing that intratumor C. parvum favors 
the generation of T  cell-mediated immunity. It will be shown in the following paper 
(17)  that  the onset of regression of a  tumor containing  C. parvurn is preceded by an 
augmented production ofT ceils that are specifically cytolytic for P815 target cells in 
vitro. 
This type of evidence does not prove, however, that the regression of the C. parvum- 
treated tumor was caused by T  cell-mediated immunity. It is possible, instead, that 
the generation of T  cell-mediated immunity was the result, rather than the cause, of 
tumor  regression,  in  the  same  way  that  anti-tumor  immunity  develops  after  an 
immunogenic  tumor  is  removed by ligation  or excision  (20,  21).  It  is  possible,  for 
example,  that  the  tumor  was  caused  to  regress  nonspecifically  as  the  result  of a 
mechanism directed against intratumor C. parvum. For this reason, it was significant 
to  demonstrate  that  growth  and  regression  of the  C. parvum-treated  tumor  in  one 
footpad was accompanied by concordant growth and regression of an untreated  test 
tumor growing in the contralateral footpad. The close temporal relationship between 
the  onset  of  regression  of  the  treated  tumor  and  distant  test  tumor  favors  the 
interpretation  that  the  anti-tumor  mechanism  generated  against  the  former  was 
distributed systemically to cause regression of the latter. Because the passive transfer 
of large volumes of serum from mice whose C. parvum-treated  tumors were regressing 
failed to confer any anti-tumor immunity on normal recipients, it is almost certain 
that  the  destruction  of the  distant  test  tumor  was  achieved  by  T  cell-mediated 
immunity  rather  than  humoral  immunity.  A  similar  therapeutic  effect  against  a 
distant test tumor was demonstrated when gamma-irradiated, nonreplicating tumor 
cells were substituted for living tumor cells in the therapeutic admixture. The results 
indicate that this type of immunotherapy theoretically should be capable of specifi- 
cally eliminating distant metastases. 618  ANTI-TUMOR ACTION  OF  CORYNEBACTERIUM PARVUM 
Even so, the therapeutic effect of giving an admixture of replicating or nonrepli- 
eating tumor cells admixed with C. parvum is limited to test tumors of relatively small 
size. Indeed, in agreement with the findings of others (7, 8), the therapeutic effect of 
such an admixture was shown here to be greatest when the admixture was injected 
before the test tumor was implanted. The reason for this was shown by an experiment 
designed to determine the therapeutic effect of injecting the admixture at different 
times  before and  after implanting  the  test  tumor  in  the  contralateral  foot.  It  was 
found that the onset of regression of the test tumor always occurred between 8 and  10 
d after injecting the admixture. This meant that the earlier the admixture was given 
relative to implanting the  test  tumor,  the less time there was for the test  tumor to 
grow  before  the  onset  of regression.  Consequently,  injecting  the  admixture  either 
before, or at the time of implanting the test tumor resulted in complete regression of 
relatively small tumors. In contrast, injecting the admixture after implanting the test 
tumor resulted in the partial regression of much larger tumors. It was not surprising 
to find, therefore, that practically no therapeutic effect was expressed at all against a 
6-d  test  tumor.  It  is  apparent,  then,  that  immunotherapy  of an  established  P815 
tumor with an admixture of tumor cells and C. parvum is limited, at least in part, by 
the  time it  takes  for T  cell-mediated immunity to be generated  in  response to the 
admixture. The following paper (17) will show that it takes 9-10 d  for the admixture 
to cause peak production of cytolytic T  cells in the draining node and spleen. This 
means that  injecting a  therapeutic admixture of C. parvum and tumor cells with the 
hope of causing the regression of a  6-d test tumor represents an attempt to regress a 
tumor that will undergo an additional 9-10 d  growth before enough cytolytic T  cells 
are generated to destroy it. Considering the rapid rate at which most murine tumors 
grow,  this  would  be an  enormous tumor burden  for immunotherapy  to  eliminate. 
Tumor burden, however, may not prove to be the major obstacle to immunotherapy. 
Recent  work  performed  in  this  laboratory  shows  (22,  23),  for  example,  that  it  is 
possible to cause the regression of very large tumors in recipient mice by the passive 
transfer of tumor-sensitized T  cells from immune donors, provided the recipients have 
been  made  T  cell  deficient  by  thymectomy  and  irradiation.  It  was  shown  that 
passively transferred,  sensitized T  cells fail to cause regression of tumors in T  cell- 
intact  recipients  because  these  recipients  possess  a  tumor-induced  state  of T  cell- 
mediated  immunosuppression  that  inhibits  the  anti-tumor  action  of the  infused 
effector cells. The possibility that this mechanism of immunosuppression is responsible 
for the  failure of C. parvum to cause  the  regression  of relatively large tumors  must 
therefore be considered. 
Summary 
The  anti-tumor  mechanism  in  mice  induced  by  a  subcutaneous  injection  of 
syngeneic tumor cells  admixed  with  Corynebacterium parvum was  investigated.  When 
mice were implanted in a  hind footpad with 2 X  l0  s tumor cells admixed with  100 
I~g  C. parvum, the  tumor  that  emerged  grew  progressively for about  9  d  and  then 
underwent  progressive and  complete  regression.  It  was  found  that  this  C.  parvum- 
induced regression was associated with the acquisition of a systemic, T  cell-mediated 
mechanism of immunity to tumor-specific transplantation  antigens,  which  enabled 
the host to cause the regression of an untreated test tumor growing simultaneously at 
a  distant  site.  The  generation  of a  C. parvum-potentiated  anti-tumor  response was E.  S.  DYE,  R. J.  NORTH,  AND C.  D.  MILLS  619 
dependent on  the presence of tumor cells in close association with  C. parvum,  tumor 
immunogenicity,  and  the  quantity  of tumor  antigen  in  the  admixture.  The  anti- 
tumor immunity was specific for the tumor in the therapeutic admixture and could 
be adoptively transferred to normal recipients with Thy-1.2-positive lymphocytes, but 
not with serum. Complete regression of a  distant test tumor by the C. parvum-tumor 
admixture was limited to tumors below a  certain critical size. 
Received  for publication 4 May 1981. 
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